Dateline City:
WHITEHOUSE STATION, N.J.
Marketing Authorization Application also Filed with the European Medicines Agency
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that its New Drug Application for an investigational
intravenous (IV) solution formulation of the company's antifungal agent,
NOXAFIL (posaconazole), has been accepted for priority
review by the U.S. Food and Drug Administration (FDA).
Language:
English
Contact:
MerckMedia Contacts:Pam Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestor Contacts:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more